Cargando…
Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial
OBJECTIVES: To determine the efficacy of adding abacavir (Ziagen, ABC) to optimal stable background antiretroviral therapy (SBG) to AIDS dementia complex (ADC) patients and address trial design. DESIGN: Phase III randomized, double-blind placebo-controlled trial. SETTING: Tertiary outpatient clinics...
Autores principales: | Brew, Bruce J, Halman, Mark, Catalan, Jose, Sacktor, Ned, Price, Richard W, Brown, Steve, Atkinson, Hamp, Clifford, David B, Simpson, David, Torres, Gabriel, Hall, Colin, Power, Christopher, Marder, Karen, Arthur, Justin C. Mc, Symonds, William, Romero, Carmen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1845158/ https://www.ncbi.nlm.nih.gov/pubmed/17401456 http://dx.doi.org/10.1371/journal.pctr.0020013 |
Ejemplares similares
-
Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014) -
AIDS Dementia Complex
por: Brew, Bruce J., et al.
Publicado: (1988) -
Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research
por: Levine, Andrew, et al.
Publicado: (2020) -
Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015) -
Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)